Tanox Inc. About
Tanox Inc. Tanox, Inc. discovers and develops therapeutic
monoclonal antibodies to address unmet medical needs in the areas of asthma, allergy,
inflammation, diseases affecting the human immune system and infectious diseases.
In 2003, an anti-IgE therapy, Xolair® (Omalizumab) for Subcutaneous Use,
received approval from the U.S. Food and Drug Administration for the treatment
of adults and adolescents (12 years of age and above) with moderate-to-severe
persistent asthma who have a positive skin test or in vitro reactivity to a perennial
aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.
The Company's products are genetically engineered antibodies that target
a specific molecule or antigen. TNX -355 HIV/AIDS --Target -CD4 Cells
More About Tanox